JP2023530785A - {2-[3-シクロヘキシル-3-(trans-4-プロポキシ-シクロヘキシル)-ウレイド]-チアゾール-5-イルスルファニル}-酢酸の結晶形およびその使用 - Google Patents
{2-[3-シクロヘキシル-3-(trans-4-プロポキシ-シクロヘキシル)-ウレイド]-チアゾール-5-イルスルファニル}-酢酸の結晶形およびその使用 Download PDFInfo
- Publication number
- JP2023530785A JP2023530785A JP2023519156A JP2023519156A JP2023530785A JP 2023530785 A JP2023530785 A JP 2023530785A JP 2023519156 A JP2023519156 A JP 2023519156A JP 2023519156 A JP2023519156 A JP 2023519156A JP 2023530785 A JP2023530785 A JP 2023530785A
- Authority
- JP
- Japan
- Prior art keywords
- crystalline form
- peaks
- xrpd pattern
- theta
- degrees
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026034319A JP2026108667A (ja) | 2020-06-08 | 2026-03-04 | {2-[3-シクロヘキシル-3-(trans-4-プロポキシ-シクロヘキシル)-ウレイド]-チアゾール-5-イルスルファニル}-酢酸の結晶形およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063035994P | 2020-06-08 | 2020-06-08 | |
| US63/035,994 | 2020-06-08 | ||
| PCT/US2021/036082 WO2021252309A1 (en) | 2020-06-08 | 2021-06-07 | Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026034319A Division JP2026108667A (ja) | 2020-06-08 | 2026-03-04 | {2-[3-シクロヘキシル-3-(trans-4-プロポキシ-シクロヘキシル)-ウレイド]-チアゾール-5-イルスルファニル}-酢酸の結晶形およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023530785A true JP2023530785A (ja) | 2023-07-19 |
| JP2023530785A5 JP2023530785A5 (cg-RX-API-DMAC7.html) | 2024-06-13 |
Family
ID=78846441
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023519156A Pending JP2023530785A (ja) | 2020-06-08 | 2021-06-07 | {2-[3-シクロヘキシル-3-(trans-4-プロポキシ-シクロヘキシル)-ウレイド]-チアゾール-5-イルスルファニル}-酢酸の結晶形およびその使用 |
| JP2026034319A Pending JP2026108667A (ja) | 2020-06-08 | 2026-03-04 | {2-[3-シクロヘキシル-3-(trans-4-プロポキシ-シクロヘキシル)-ウレイド]-チアゾール-5-イルスルファニル}-酢酸の結晶形およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026034319A Pending JP2026108667A (ja) | 2020-06-08 | 2026-03-04 | {2-[3-シクロヘキシル-3-(trans-4-プロポキシ-シクロヘキシル)-ウレイド]-チアゾール-5-イルスルファニル}-酢酸の結晶形およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4161639A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023530785A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230048501A (cg-RX-API-DMAC7.html) |
| CN (2) | CN116056760A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021289591A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3181665A1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2022015524A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021252309A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3093025A1 (en) | 2018-06-12 | 2019-12-19 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
| US12391658B2 (en) | 2020-02-18 | 2025-08-19 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| US12479808B2 (en) | 2020-06-08 | 2025-11-25 | Vtv Therapeutics Llc | Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016510741A (ja) * | 2013-03-04 | 2016-04-11 | ブイティーブイ・セラピューティクス・エルエルシー | グルコキナーゼ活性化剤を含む固体組成物ならびにその同じものを作製および使用する方法 |
| JP2016513625A (ja) * | 2013-03-04 | 2016-05-16 | ブイティーブイ・セラピューティクス・エルエルシー | 安定なグルコキナーゼ活性化剤組成物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0506662B8 (pt) * | 2004-01-06 | 2021-05-25 | Novo Nordisk As | compostos ativadores de glucoquinase |
| PT2576524T (pt) * | 2010-05-26 | 2017-11-17 | Vtv Therapeutics Llc | Resumo |
| IN2014DN09554A (cg-RX-API-DMAC7.html) * | 2012-05-17 | 2015-07-17 | Transtech Pharma Llc | |
| DK3556354T3 (da) * | 2016-12-15 | 2025-08-04 | Hua Medicine Shanghai Ltd | Oral fremstilling af en glucokinaseaktivator og fremgangsmåde til fremstilling deraf |
-
2021
- 2021-06-07 CA CA3181665A patent/CA3181665A1/en active Pending
- 2021-06-07 CN CN202180056233.1A patent/CN116056760A/zh active Pending
- 2021-06-07 WO PCT/US2021/036082 patent/WO2021252309A1/en not_active Ceased
- 2021-06-07 KR KR1020237000609A patent/KR20230048501A/ko active Pending
- 2021-06-07 EP EP21821691.9A patent/EP4161639A4/en active Pending
- 2021-06-07 JP JP2023519156A patent/JP2023530785A/ja active Pending
- 2021-06-07 MX MX2022015524A patent/MX2022015524A/es unknown
- 2021-06-07 CN CN202511373032.0A patent/CN121202809A/zh active Pending
- 2021-06-07 AU AU2021289591A patent/AU2021289591A1/en active Pending
-
2022
- 2022-12-06 MX MX2026000786A patent/MX2026000786A/es unknown
-
2026
- 2026-03-04 JP JP2026034319A patent/JP2026108667A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016510741A (ja) * | 2013-03-04 | 2016-04-11 | ブイティーブイ・セラピューティクス・エルエルシー | グルコキナーゼ活性化剤を含む固体組成物ならびにその同じものを作製および使用する方法 |
| JP2016513625A (ja) * | 2013-03-04 | 2016-05-16 | ブイティーブイ・セラピューティクス・エルエルシー | 安定なグルコキナーゼ活性化剤組成物 |
Non-Patent Citations (3)
| Title |
|---|
| BASTIN,R.J. ET AL: "Salt selection and optimization procedures for pharmaceutical new chemical entities", ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 4, JPN6009059058, 2000, pages 427 - 435, ISSN: 0005722934 * |
| 寺田勝英: "熱分析の医薬品開発への応用", NETSU SOKUTEI, vol. 38, no. 2, JPN6023001927, 2011, pages 46 - 53, ISSN: 0005722932 * |
| 山野光久: "医薬品のプロセス研究における結晶多形現象への取り組み", 有機合成化学協会, vol. 65, no. 9, JPN6023001929, 2007, pages 907 - 913, ISSN: 0005722933 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2026000786A (es) | 2026-03-02 |
| CN116056760A (zh) | 2023-05-02 |
| JP2026108667A (ja) | 2026-06-30 |
| US20230219910A1 (en) | 2023-07-13 |
| EP4161639A4 (en) | 2024-01-17 |
| AU2021289591A1 (en) | 2023-01-19 |
| MX2022015524A (es) | 2023-03-22 |
| CA3181665A1 (en) | 2021-12-16 |
| WO2021252309A1 (en) | 2021-12-16 |
| EP4161639A1 (en) | 2023-04-12 |
| CN121202809A (zh) | 2025-12-26 |
| KR20230048501A (ko) | 2023-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023202085B2 (en) | Polymorphic forms of RAD1901-2HCL | |
| JP6809681B2 (ja) | 2−ヒドロキシ−6−((2−(1−イソプロピル−1h−ピラゾール−5−イル)ピリジン−3−イル)メトキシ)ベンズアルデヒドの遊離塩基の結晶多形 | |
| EP4010322B1 (en) | Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof | |
| AU2017373784B2 (en) | Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists | |
| AU2021289591A1 (en) | Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof | |
| TW202128627A (zh) | 選擇性鉀通道調節劑之固態晶型 | |
| US12479808B2 (en) | Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof | |
| JP2016512516A (ja) | キナゾリン誘導体の固体形態およびbraf阻害剤としてのその使用 | |
| CN113754596A (zh) | 一种吉非替尼的共晶体 | |
| RU2710230C1 (ru) | Аминный сольват ингибитора натрий-глюкозного котранспортера и способ его получения и его применение | |
| CN114075169B (zh) | 奥希替尼药用共晶体及其制备方法 | |
| HK40131995A (en) | Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and uses thereof | |
| JP2025525475A (ja) | N-[4-(4-[[2-(ジメチルアミノ)エチル]アミノ]-3-メチル-1H-ピラゾロ[3,4-d]ピリミジン-6-イル)-2-フルオロフェニル]-2,5-ジフルオロベンゼンスルホンアミドの塩及びそれらの結晶形態 | |
| US20250304635A1 (en) | Birinapant polymorph h | |
| US20230147121A1 (en) | Compositions of solid forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide | |
| HK40119275A (en) | Co-crystal forms of a novobiocin analog and proline | |
| HK40079891A (en) | Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists | |
| HK40120019A (en) | Solid state crystalline forms of a selective potassium channel modulator | |
| HK40079890A (en) | Compositions and methods related to picolinylpiperidine 5-ht1f agonists | |
| EA052101B1 (ru) | Ингибирующее p2x3 соединение, его соль, его полиморф и его применение | |
| CN112823161B (zh) | 共晶体及其用途 | |
| HK40074778A (en) | Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof | |
| HK40074778B (en) | Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof | |
| EP2280980A1 (en) | Crystalline form of n-[[4-fluoro-2-(5-methyl-1h-1,2,4-triazol-1-yl)phenyl]methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide, sodium salt monohydrate | |
| EA046754B1 (ru) | Композиция, связанная с пиридиноилпиперидиновыми агонистами 5-ht1f |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230209 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240605 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240605 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250116 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250401 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250716 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20251104 |